Author

admin

Browsing

The NASDAQ Biotechnology Index (INDEXNASDAQ:NBI) is still trading at three-year highs, despite current market volatility, in response to breakthrough innovations and increased deals involving biotech stocks listed on the NASDAQ.

After dropping to a low of 3,637.05 in October 2023, the index climbed to a nearly three year peak of 4,954.813 on September 19, 2024. While the index had pulled back to 4,243.7 as of March 31, 2025, further growth could be in store in the future.

According to a Towards Healthcare analyst report, the global biotech market is expected to grow at a compound annual growth rate of 12.5 percent from now to 2034, reaching a valuation of US$5.036 trillion.

Driving that growth will be favorable government policies, investment in the sector, increased demand for synthetic biology and a rise in chronic disorders such as cancer, heart disease and hypertension.

The top NASDAQ biotech stocks have seen sizeable share price increases over the past year. For those interested in investing in biotech companies, the best-performing small-cap biotech stocks are outlined below.

Data was gathered on March 31, 2025, using TradingView’s stock screener. Small-cap biotech stocks with market caps between US$50 million and US$500 million at that time were considered for this list.

1. Bright Minds Biosciences (NASDAQ:DRUG)

Company Profile

Year-over-year gain: 2,942.02 percent
Market cap: US$254.99 million
Share price: US$36.20

Bright Minds Biosciences is developing novel treatments for pain and neuropsychiatric disorders such as epilepsy, post-traumatic stress disorder and difficult-to-treat depression.The company’s platform includes serotonin agonists designed to provide powerful therapeutic benefits while minimizing side effects.

Bright Minds is currently in Phase 2 clinical trials for BMB-101, a highly selective 5-HT2C receptor agonist, in adult patients with classic absence epilepsy and developmental epileptic encephalopathy.

Bright Minds’ share price rocketed upward in the fourth quarter of last year, shooting up from US$2.49 to US$38.49 in one day on October 15. The company issued a press release at the time, stating it was ‘unaware of any material changes in the company’s operations’ that would have contributed to such a rally.

The outperformance appears to be related to the October 14 news that Danish pharma company H. Lundbeck was to acquire Longboard Pharma, a company developing a 5-HT2C receptor agonist, for US$60 per share.

A few days later, Bright Minds announced a non-brokered private placement of US$35 million, which sent shares up to US$47.21 on October 18.

That same month, the company shared its collaboration with Firefly Neuroscience (NASDAQ:AIFF) to use Firefly’s Brain Network Analytics technology platform to provide a full analysis of the electroencephalogram data from Bright Minds’ BMB-101 Phase 2 clinical trial. This follows the pair’s previous successful collaboration to analyze data from Bright Minds’ first-in-human Phase 1 study of BMB-101.

In March 2025, Bright Minds expanded its Scientific Advisory Board with the addition of five experts in epilepsy research.

Bright Minds’ share price reached US$55.77, its peak for the past year, on November 6.

2. Monopar Therapeutics (NASDAQ:MNPR)

Company Profile

Year-over-year gain: 924.54 percent
Market cap: US$220.3 million
Share price: US$36.10

Clinical-stage biotech Monopar Therapeutics’ main drug candidate is its late-stage ALXN-1840 for Wilson disease. Its pipeline also includes radiopharma programs such as Phase 1-stage MNPR-101-Zr for imaging advanced cancers, as well as Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac225 for the treatment of advanced cancers.

Shares in Monopar spiked by more than 600 percent on October 24, 2024, to US$32.66 following its news release detailing its exclusive worldwide licensing agreement with Alexion, AstraZeneca’s (NASDAQ:AZN) Rare Disease unit, for ALXN-1840, a drug candidate for Wilson disease that met its primary endpoints in its Phase 3 clinical trial. Going forward, Monopar will be responsible for all future global development and commercialization activities.

Further positive news flow in December continued to drive the company’s stock value. Early in the month, the company shared that the first patient was dosed with MNPR-101-Lu in its Phase 1a trial for the radiopharmaceutical. A few weeks later, Monopar announced the launch of a US$40 million concurrent public offering and private placement. After having fallen back to the US$22 range, shares in the company climbed to US$30.68 on December 17, 2024.

Positive sentiment in the company and the biotech market would later drive the stock up to its yearly high of US$51.89 on February 10, 2025. Monopar released its Q4 and full-year 2024 results on March 31.

3. Candel Therapeutics (NASDAQ:CADL)

Company Profile

Year-over-year gain: 268.3 percent
Market cap: US$262.39 million
Share price: US$5.64

Candel Therapeutics is a biotech company focused on developing oncology treatments. The company’s pipeline includes two clinical-stage multimodal biological immunotherapy platforms.

Candel’s lead product candidate, CAN-2409, is in a Phase 2 clinical trial in non-small cell lung cancer and borderline resectable pancreatic cancer, as well as Phase 2 and 3 trials for localized, non-metastatic prostate cancer.

The company had a number wins with the US Food and Drug Administration (FDA) in 2024. In February and May, respectively, Candel’s CAN-3110 received regulatory approval for fast-track designation and orphan drug designation for the treatment of recurrent high-grade glioma.

The agency also granted Candel orphan drug designation for CAN-2409 for the treatment of pancreatic cancer in April 2024. Positive interim data for the trial on pancreatic cancer released that month, sent the company’s share price spiking upward. It ultimately climbed to its 2024 high point of US$14.00 on May 15, 2024.

So far in 2025, Candel’s share price has traded as high as US$12.21 on February 20. In its January corporate update, the company shared its goals for the year, including aiming for Q4 for reporting overall survival data in patients with recurrent high-grade glioma from its ongoing phase 1b trial that is evaluating multiple doses of CAN-3110.

4. Tiziana Life Sciences (NASDAQ:TLSA)

Company Profile

Year-over-year gain: 154.76 percent
Market cap: US$119.51 million
Share price: US$1.08

Tiziana Life Sciences is a clinical-stage biopharma which is developing therapies for autoimmune and inflammatory diseases, degenerative diseases, and cancer-related to the liver. Its pipeline of candidates is built on its patent drug delivery technology that provides a possible alternative to intravenous (IV) delivery. Tiziana’s lead candidate is intranasal foralumab, which it says is the only fully human anti-CD3 mAb currently in clinical development.

On May 31, 2024, shares in Tiziana broke above US$1 after a series of positive news flow for the company. This included positive clinical results from its intermediate sized Expanded Access Program for non-active secondary progressive multiple sclerosis patients, which demonstrated multiple improvements in foralumab-treated patients, as well as its submission of an orphan drug designation application to the FDA for intranasal foralumab for the treatment of non-active secondary progressive multiple sclerosis (na-SPMS).

While Tiazana’s share price slid back down below US$1 per share by mid-June 2024, news that the FDA granted fast track designation to Tiziana intranasal foralumab for the treatment of na-SPMS gave it a much needed boost to the upside. By August 12, the stock’s value had risen to US$1.45 per share.

Tiziana Life Sciences shares reached a yearly peak of US$1.69 on March 7, 2025, after the company filed its investigational new drug application to the FDA for a phase 2 clinical trial in amyotrophic lateral sclerosis (ALS), which is supported by the ALS Association.

5. Benitec Biopharma (NASDAQ:BNTC)

Company Profile

Year-over-year gain: 149.71 percent
Market cap: US$331.43 million
Share price: US$13.01

California-based Benitec Biopharma is advancing novel genetic medicines via its proprietary “Silence and Replace” DNA-directed RNA interference platform. The company is currently focused on developing therapeutics for chronic and life-threatening conditions, including oculopharyngeal muscular dystrophy (OPMD).

Its drug candidate BB-301 was granted orphan drug designation by the FDA and the European Medicines Agency. Benitec is well funded to advance its BB-301 clinical development program through the end of 2025.

Benitec’s share price benefited from its first bump of the past year, after the company released its fiscal year Q3 2024 update in mid-May highlighting its achievements over the quarter. This included the closing of a US$40 million private placement. Benitec’s stock value hit US$10.47 per share on May 20, 2024.

Later in the fall, the company reported positive data from two patients with OPMD treated with low-dose BB-301 in phase 1b/2a study, showing the clinical trial is meeting key safety and efficacy endpoints. Shares hit another high of US$11.22 on October 17, 2024.

Benitec’s share price hit US$16.79, its highest yearly value to date, on March 20, 2025, a day after the company released positive interim clinical results for three patients with OPMD treated with BB-301 in phase 1b/2a study.

“The sixth and final Subject of Cohort 1 will be treated with BB-301 in the second calendar quarter of this year, and we are highly optimistic about the potential for continued benefit in Subjects enrolled in the ongoing clinical study,” said Jerel A. Banks, Benitec Executive Chairman and CEO.

Securities Disclosure: I, Melissa Pistilli, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

StrategX Elements Corp. (CSE: STGX) (‘StrategX’ or the ‘Company’) announces that Gary Wong has stepped down from his role as the Company’s Vice President of Exploration. While Gary is transitioning from this position, he will continue to contribute to other capacities, bringing his expertise and leadership to key projects. The Board would like to thank Gary for his efforts and contributions over the past two years.

About StrategX
StrategX is an exploration company focused on discovering critical metals in northern Canada. With projects on the East Arm of the Great Slave Lake (Northwest Territories) and the Melville Peninsula (Nunavut), the Company is pioneering new district-scale discoveries in these underexplored regions. By integrating historical data with modern exploration techniques, StrategX provides investors with a unique opportunity to participate in discovering essential metals crucial to electrification, global green energy, and supply chain security.

On Behalf of the Board of Directors

Darren G. Bahrey
CEO, President & Director

For further information, please contact:

StrategX Elements Corp.
info@strategXcorp.com
Phone: 604.379.5515

For further information about the Company, please visit our website at www.strategXcorp.com.

Neither the Canadian Securities Exchange nor its regulation services accept responsibility for the adequacy or accuracy of this release.

Disclaimer for Forward-Looking Information
All statements included in this press release that address activities, events, or developments that the Company expects, believes, or anticipates will or may occur in the future are forward-looking statements. These forward-looking statements involve numerous assumptions made by the Company based on its experience, perception of historical trends, current conditions, expected future developments and other factors it believes are appropriate in the circumstances. In addition, these statements involve substantial known and unknown risks and uncertainties that contribute to the possibility that the predictions, forecasts, projections, and other forward-looking statements will prove inaccurate, certain of which are beyond the Company’s control. Readers should not place undue reliance on forward-looking statements. Except as required by law, the Company does not intend to revise or update these forward-looking statements after the date hereof or revise them to reflect the occurrence of future unanticipated events.

Not for distribution to United States newswire services or for dissemination in the United States.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/247050

News Provided by Newsfile via QuoteMedia

This post appeared first on investingnews.com

NEWYou can now listen to Fox News articles!

The billion-dollar diversity, equity and inclusion (DEI) industry has infiltrated every sector of society, from corporate boardrooms to government agencies. In the public sector, it has morphed into a boondoggle, funneling taxpayer dollars into products and programs aimed at indoctrinating Americans under the guise of progress. A recent X post by Secretary Brooke Rollins at the U.S. Department of Agriculture (USDA) exemplifies this overreach, exposing how the Biden administration politicized even the most basic agricultural resources — seeds — turning them into vehicles for DEI propaganda. 

Rollins recently posted an image of USDA tomato seed packets found behind a door emblazoned with the words, ‘These seeds are for growing, diversity, equity, inclusion, and accessibility at USDA.’ With the seeds were decorative note cards that stated: ‘If You Can Be Anything, Be Inclusive At USDA.’  

The DEI seed initiative seems to have been an outgrowth of President Joe Biden’s Executive Order 13985, signed in January 2021, which mandated equity action plans across federal agencies. Biden’s EO was issued to encourage workers to seek ways of embedding DEI into their agencies. It no doubt is responsible for much government waste, and, as Rollins said, ‘There will be no more American taxpayer dollars spent on DEI initiatives or #WOKESEEDS at the @USDA.’ 

In the meantime, farmers dependent on USDA to focus on its mission suffered along with other Americans. According to data gleaned from the U.S. Bureau of Labor, while farmers grappled with real challenges — food inflation surged 23.5% between February 2020 and May 2023, and fertilizer prices spiked 300% in 2022 — the USDA diverted resources to ideological endeavors. 

The department’s agenda ranged from items such as the seeds to a study with the claim, ‘It is also important to recognize that transgender men and people with masculine gender identities, intersex and non-binary persons may also menstruate.’ The result? Wasted taxpayer money and propaganda infiltrating even the seeds meant to grow America’s food supply. 

This isn’t just about a waste of taxpayer dollars; it’s a betrayal of public trust. During Biden’s tenure, farmers faced supply chain disruptions and regulatory burdens, yet the USDA prioritized DEI initiatives over practical support like securing food supply chains or reducing red tape.  

The absurdity of DEI seed packets — some users even questioned if they could be used to grow tomatoes — underscores the overreach of the previous administration’s woke agenda. A 2025 White House directive, which terminated all ‘Equity Action Plans’ and related grants, labeled such initiatives as ‘immense public waste’ and discriminatory, aligning with Rollins’ move to end this spending at the USDA. This policy shift, reinforced by the America First Investment Policy introduced in February 2025, redirects resources to agricultural innovation, not ideological agendas. 

The USDA’s DEI seeds are a microcosm of a larger problem: the billion-dollar DEI industry has overstepped, using taxpayer dollars to push propaganda at the expense of practical governance. Rollin’s approach is balanced and practical. USDA should focus on food security over symbolic gestures like DEI seeds. Rollins’ decision to expose the waste and reassure Americans of her commitment to running a responsible Department of Agriculture is a healthy signal of a return to accountability that will ensure that taxpayer dollars support American farmers, not ideological indoctrination.  

Ferreting out wasted funds that undergirded the politicized agendas of the Biden administration sends a strong message to other federal agencies that they too need to closely examine their agencies. This should guarantee that commonsense and accountability are working together to ensure that legally prohibited, divisive DEI initiatives are being brought into alignment with civil rights laws and constitutional protections. 

This post appeared first on FOX NEWS

Vice President JD Vance condemned European countries last month for a lack of commitment to democracy as many of them lash out with lawfare attacks against populist leaders.

Vance’s critique applies to more than just Europe, however, as populist leaders across the globe are facing legal troubles from outright election bans to criminal convictions.

Here are the top populist leaders facing the most pressure.

1. Marine Le Pen, France

Right-wing French politician Marine Le Pen and several members of her ascendant National Rally party were convicted of embezzlement on Monday, and she herself has been banned from running in the 2027 presidential election.

Populist leaders from across Europe condemned the verdict, pointing to her significant lead in the polls.

‘Those who fear the judgment of voters often seek reassurance from the courts. In Paris, they have condemned Marine Le Pen and would like to remove her from political life,’ Italian Deputy Prime Minister Matteo Salvini said following Le Pen’s verdict.

‘We are not intimidated,’ he added. ‘Full speed ahead, my friend!’

2. Jair Bolsonaro, Brazil

Brazil’s Supreme Court accepted charges against former President Jair Bolsonaro last week over an alleged attempt to remain in office after his 2022 election defeat, ordering the former leader to stand trial.

All five justices ruled in favor of accepting the charges leveled by Prosecutor-General Paulo Gonet, who accused Bolsonaro and 33 others of attempting a coup that included a plan to poison his successor, current President Luiz Inácio Lula da Silva, and kill a Supreme Court judge.

The former president has repeatedly denied wrongdoing and says he’s being politically persecuted.

Under Brazilian law, a coup conviction carries a sentence of up to 12 years. When combined with the other charges, it could result in a sentence of decades behind bars.

3. Calin Georgescu, Romania

Calin Georgescu won the first round of Romania’s presidential elections earlier this year, only for the election to be canceled due to allegations of Russian collusion in Georgescu’s favor.

Georgescu was then taken into custody and has since been banned from running in the election, despite leading in polls.

4. Matteo Salvini, Italy

Italian Vice Premier Matteo Salvini faced years of legal trouble due to accusations that he had illegally detained roughly 100 migrants during his term as interior minister in 2019.

The 2019 incident saw migrants held offshore on a humanitarian rescue ship. Italian courts dropped the charges against Slavini in December.

‘Protecting our country’s borders from smugglers is not a crime,’ Salvini said shortly after the verdict. ‘This is a victory for the League and for Italy.’

5. Imran Khan, Pakistan

Pakistan’s former Prime Minister Imran Khan was jailed last month on corruption charges, though many of his supporters have compared his situation to that of President Donald Trump and the charges he has faced.

A Pakistani court sentenced Khan and his wife, Bushra Bibi, to 14 and seven years in jail after finding them guilty of corruption. They were convicted for allegedly accepting land as a bribe through the Al-Qadir Trust, which they had set up while Khan was in office. Khan, however, maintains his innocence, describing the events as a ‘witch hunt’ in exclusive comments to Fox News Digital. It is just one of the more than 100 cases he is facing.

Khan’s plight has also been highlighted by longtime Trump ally and adviser Richard Grenell, who took to social media late last year when he tweeted, ‘Free Imran Khan!’

6. Donald Trump, United States of America

President Donald Trump has faced waves of legal trouble from his political opponents stretching back nearly a decade to his first administration.

First he faced down the now-discredited Russia collusion claims before once again facing impeachment for negotiating aid for Ukraine. Once out of office, federal and state governments targeted his business dealings with investigations, eventually resulting in his conviction for falsifying business records, a verdict his allies say was bogus.

Trump has acknowledged that populist leaders like him are facing challenges across the globe. He remarked on Le Pen’s ‘very important’ situation in a statement Tuesday.

‘She was banned for five years and she was the leading candidate,’ Trump said. ‘That sounds like this country, that sounds very much like this country.’

Fox News’ Avi Kumar, Benjamin Weinthal and the Associated Press contributed to this report.

This post appeared first on FOX NEWS

The legal resistance to President Donald Trump’s second term is in full swing with more than 120 lawsuits filed since Jan. 20 by states, advocacy groups and individuals targeting his executive orders and policy agenda.

As the lawsuits move through the judiciary, understanding the structure of the federal court system can help clarify how these challenges are likely to unfold.

Article III of the U.S. Constitution establishes the Supreme Court along with ‘inferior Courts as the Congress may from time to time ordain and establish.’ The Constitution also states that judges shall hold their offices during a period of ‘good behavior.’

The federal judiciary has three main levels: district courts (trial courts), circuit courts (the first level of appeal) and the Supreme Court (the final appellate authority). There are 94 district courts, 13 circuit courts and one Supreme Court.

To hear a case, a court must have personal jurisdiction (authority over the parties involved), subject matter jurisdiction (authority to hear the type of legal issue at hand) and proper venue (the correct geographic location for the case to be tried).

Unlike state courts, which have broad authority, federal courts are courts of ‘limited jurisdiction,’ which means they can only hear cases authorized by the Constitution or federal law. Each lawsuit filed against the Trump administration raises a federal question, giving federal courts subject-matter jurisdiction.

Each district court has at least one United States district judge appointed by the president and confirmed by the Senate for a life term. Plaintiffs who lose at the district court level can appeal to a federal appellate court.

Appellate courts, also known as circuit courts, hear appeals from district courts within their geographic boundaries. Each circuit covers multiple states. For example, the Fifth Circuit includes Louisiana, Mississippi and Texas.

Each circuit also has multiple judges, ranging from six total judges to 29. Appeals to the circuit courts are first heard by a panel of three judges. Parties must file briefs to the court, arguing why the trial court’s decision should either be affirmed or reversed.

After briefs are filed, oral arguments are scheduled during which attorneys from both sides present their case and answer questions from a panel of judges. In some instances, the full court may hear a case in what’s called an en banc session. The Ninth Circuit, due to its size, follows a modified en banc process.

A circuit court’s decision is binding on all lower courts within that circuit. As such, those courts must follow that holding. Other circuits can look to that circuit’s holding as reference, but they are not bound by it.

A case can generally only be appealed once a final decision has been issued. However, some issues can be appealed before a final decision is made via what’s called an interlocutory appeal.

Parties can appeal a circuit court’s decision to the U.S. Supreme Court by filing a writ of certiorari, which is a request for the court to review the case. The Supreme Court isn’t required to take the case and denies most petitions, granting review in less than 1% of appeals. When cert is denied, the lower court’s ruling remains in place.

A circuit split is when circuits disagree on a particular legal matter. This will generally prompt the Supreme Court to grant cert in a case. If cert is granted, parties must file briefs and conduct oral arguments. 

Each circuit is assigned to a specific Supreme Court justice who handles certain appeals from that region, such as emergency applications and administrative requests. For example, Chief Justice Roberts oversees the D.C. Circuit, the 4th Circuit and the Federal Circuit. The assigned justice may act alone or refer the matter to the full court at their discretion.

The Trump administration has already appealed various decisions to the Supreme Court via emergency appeals. On March 28, the administration asked the court to review a temporary restraining order that blocked the administration’s use of an 18th-century wartime law to deport Venezuelan nationals, including alleged members of the gang Tren de Aragua, from the United States. 

The appeal came shortly after the U.S. Court of Appeals for the D.C. Circuit issued a 2-1 ruling to uphold the district court’s decision blocking the administration. 

Fox News Digital’s Breanne Deppisch contributed to this report. 

This post appeared first on FOX NEWS

The Senate Judiciary Committee is holding a hearing to examine the influx of nationwide orders against the Trump administration by federal district judges. 

Last week, Chairman Chuck Grassley, R-Iowa, revealed the details of the event, set one day after the House committee’s hearing on the same subject. 

‘Since the courts and the executive branch are on an unsustainable collision course, Congress must step in and provide clarity,’ he said in a statement last week. ‘Our hearings will explore legislative solutions to bring the balance of power back in check.’

The hearing, titled, ‘Rule by District Judges II: Exploring Legislative Solutions to the Bipartisan Problem of Universal Injunctions,’ will feature testimony from John N. Matthews Professor of Law at Notre Dame Samuel Bray, partner at Boies Schiller Flexner Jesse Panuccio, who was previously the acting associate attorney general at the Department of Justice (DOJ), and the chairman of the DOJ’s Regulatory Reform Task Force and vice chairman of the DOJ’s Task Force on Market Integrity and Consumer Fraud, as well as Agnes Williams Sesquicentennial Professor of Federal Courts at Georgetown University Law Center Stephen I. Vladeck.

After revealing details of the hearing, Grassley rolled out his own bill to tackle the issue. 

‘These nationwide injunctions have become a favorite tool for those seeking to obstruct Mr. Trump’s agenda,’ he wrote in an op-ed in the Wall Street Journal. ‘More than two-thirds of all universal injunctions issued over the past 25 years were levied against the first Trump administration. In the past two months alone, judges have issued at least 15 universal injunctions against the administration—surpassing the 14 President Biden faced throughout his four-year term.’

Grassley’s legislation would restrain the lower courts’ ability to issue nationwide orders, and they would no longer be able to stop ‘legitimate executive action’ by granting orders to entities or individuals who are not parties to the lawsuit. 

While similar bills have been introduced by Grassley’s GOP colleagues in both the Senate and House, it is unclear whether the issue will get floor votes, as it would need to amass more than 60 votes in the upper chamber to beat the filibuster. 

Senate Majority Leader John Thune, R-S.D., has not elaborated much on the issue and, when asked about it, he told reporters, ‘At the end of the day, there is a process, and there’s an appeals process. And, you know, I suspect that’s ultimately how it’s going to be ended.’

President Donald Trump has made his frustration with nationwide injunctions clear, urging action on them publicly. 

‘Unlawful Nationwide Injunctions by Radical Left Judges could very well lead to the destruction of our Country!’ the president said in a recent Truth Social post. ‘These people are Lunatics, who do not care, even a little bit, about the repercussions from their very dangerous and incorrect Decisions and Rulings.’

‘If Justice Roberts and the United States Supreme Court do not fix this toxic and unprecedented situation IMMEDIATELY, our Country is in very serious trouble!’ he continued. 

This post appeared first on FOX NEWS

Democrats have remained relatively quiet while President Donald Trump and Republicans hammer federal district judges for churning out nationwide orders halting his administration’s actions. 

But during President Joe Biden’s tenure, they decried similar wide-ranging injunctions and even sought to remedy the issue with legislation. 

In 2023, Sen. Mazie Hirono, D-Hawaii, debuted a measure to give the U.S. District Court for the District of Columbia sole jurisdiction over any cases with national implications. 

‘When parties are able to choose their judges, it creates the perception that they are able to predetermine their case’s outcome, compromising the integrity of our federal justice system,’ she said in a statement at the time. 

‘Activist plaintiffs should not be able to hand-pick individual judges to set nationwide policy, which is why it’s critical we address the issue of judge shopping in our federal courts. By routing cases with national implications through the D.C. District Court, which has expertise in cases challenging federal agency action, the Stop Judge Shopping Act will strengthen trust in our federal justice system and help ensure major cases are decided based on the law, not the ideological agenda of any one judge.’

The bill wouldn’t have ended nationwide injunctions as Republicans and Trump have sought, but it would give all jurisdiction on such decisions to one court, potentially reducing the probability of such orders being levied against Biden or other Democrat presidents. 

The D.C. court is made up of 11 district judges appointed by former Presidents Biden and Barack Obama, and four were appointed by Trump. The court’s chief judge is Obama-appointee James Boasberg, who is at the center of a key battle with the Trump administration over deportation flights using the Alien Enemies Act, a 1798 wartime immigration law. 

A similar measure was proposed by then-Majority Leader Chuck Schumer, D-N.Y., Sen. Sheldon Whitehouse, D-R.I., in addition to 37 other Democrats in 2024. The bill would have required cases involving broad injunctions to be randomly assigned in order to ‘promote uniformity and fairness.’

Hirono, Schumer and Whitehouse did not provide comment to Fox News Digital when asked if they still supported legislative action and if they backed any of the Republican bills. 

Multiple Republicans in Congress have rolled out legislation this Congress to explicitly prevent district-level courts from issuing such wide-ranging orders, including Senate Judiciary Committee Chair Chuck Grassley, R-Iowa. 

In an op-ed for the Wall Street Journal, he wrote, ‘The obvious solution is to limit district courts to resolving the cases only between the parties before them.’

‘Under my bill, lower courts could no longer block legitimate executive action by issuing orders to nonparties to the lawsuit. The bill would also make TROs against the government immediately appealable, to make sure that prudence wins out over rash decisions handed down in the heat of a political moment,’ he explained. 

The top judiciary Republican also pointed to past grievances Democrats have had with the practice of nationwide court orders. 

‘Two-hundred forty Democratic lawmakers, including Sens. Chuck Schumer and Dick Durbin, in 2023, submitted a friend-of-the-court brief warning of the ‘perilous consequences’ resulting from a district judge’s move to block the abortion pill mifepristone,’ he recalled. 

‘Justice Elena Kagan has similarly expressed dismay.’

The brief was filed to plead with the high court to overrule the nationwide injunction issued by U.S. District Judge Matthew Kacsmaryk, which suspended FDA approval of mifepristone. 

‘The consequences of the Fifth Circuit’s decision could extend far beyond mifepristone, for it undermines the science-based, expert-driven process that Congress designed for determining whether drugs are safe and effective,’ the lawmakers wrote at the time. ‘By permitting the district court to disrupt FDA’s current regulation of mifepristone, the Fifth Circuit has countenanced judicial interference that erroneously substitutes the district court’s judgment for FDA’s scientific determination.

Hirono, Schumer and Whitehouse have not been publicly critical of nationwide injunctions during the new Trump administration as district judges across the country manage to halt actions.

On Wednesday, the Senate Judiciary Committee will hold a hearing on the subject as Republicans push legislation to end the practice of issuing nationwide orders. 

This post appeared first on FOX NEWS

Tesla CEO Elon Musk said Sunday that his involvement in the Trump administration could be hurting the automaker’s stock price.

Speaking at a town hall event in Wisconsin, Musk said his role with the so-called Department of Government Efficiency — which is pushing for widespread government job cuts — is creating backlash against his electric car company and hurting the stock.

“What they’re trying to do is put massive pressure on me, and Tesla I guess, to … stop doing this,” Musk said, according to Bloomberg News. “My Tesla stock and the stock of everyone who holds Tesla has gone, went roughly in half. I mean it’s a big deal.”

Elon Musk at a Cabinet meeting at the White House on March 24.Win McNamee / Getty Images

Shares of Tesla entered Monday already down more than 34% year to date, and the stock has been cut nearly in half from its peak in December. Shares were down an additional 6% in premarket trading Monday.

Tesla’s stock is trading at a little more than half of its highest level from December.

The drop for the stock could be a “buying opportunity” for the long term, said Musk, who was in Wisconsin ahead of a state supreme court election there. Musk has campaigned for the conservative candidate and spent more than $12 million on the race, in addition to giving $1 million each to two voters at Sunday’s rally for signing a petition against “activist judges.”

The slumping stock isn’t the only sign of public anger with Musk for his political work. Protesters demonstrated at Tesla dealerships over the weekend, and there have been reports of vandalism against vehicles and dealers across the country.

Musk’s role in politics is not limited to DOGE. He publicly campaigned with Trump in 2024 and has been a regular presence at the White House since the new administration took over in January. He also regularly comments on many different political topics on X, the social media company he owns.

The CEO’s rising political profile comes amid signs that Tesla’s core business is slowing. The automaker’s vehicle deliveries declined in 2024, and preliminary data has shown that sales are down again early this year, especially in Europe. In a note to clients Sunday, investment firm Stifel trimmed its price target on the stock and lowered its sales projections for Tesla.

Musk’s political dealings may not be the only reason for Tesla’s struggles. Other U.S. auto stocks have also labored in recent weeks, partly because of threats of higher tariffs on imported goods into the U.S. and retaliation from overseas trading partners, adding uncertainty to an industry whose supply chains are tightly woven among the U.S., Canada and Mexico.

This post appeared first on NBC NEWS

Restaurant chain Hooters of America filed for bankruptcy protection in Texas on Monday, seeking to address its $376 million debt by selling all of its company-owned restaurants to a franchise group backed by the company’s founders.

Hooters, like other casual dining restaurants, has struggled in recent years due to inflation, the high costs of labor and food and declining spending by cash-strapped American consumers. The company currently directly owns and operates 151 locations, with another 154 restaurants operated by franchisees, primarily in the United States.

The privately-owned company, which shares a private equity owner with recently-bankrupt TGI Fridays, intends to sell all corporate-owned locations to a buyer group comprised of two existing Hooters franchisees, who operate 30 high-performing Hooters locations in the U.S., mainly in Florida and Illinois.

Hooters did not disclose the purchase price of the transaction, which must be approved by a U.S. bankruptcy judge before it becomes final.

Founded in 1983, Hooters became famous for its chicken wings and its servers’ uniform of orange shorts and low-cut tank tops.

The buyer group is backed by some of Hooters’ original founders, and it pledged to take Hooters “back to its roots.”

“With over 30 years of hands-on experience across the Hooters ecosystem, we have a profound understanding of our customers and what it takes to not only meet, but consistently exceed their expectations,” said Neil Kiefer, a member of the buyer group and the current CEO of the original Hooters’ location in Clearwater, Florida.

Hooters said it expects to complete the deal and emerge from bankruptcy in three to four months. The company has lined up about $35 million in financing from its existing lender group to complete the bankruptcy transaction.

Casual dining restaurants have been hammered by rising costs in 2024, with well-known chains like TGI Fridays, Red Lobster, Bucca di Beppo, and Rubio’s Coastal Grill all filing for bankruptcy last year.

Restaurant prices have risen about 30% in the last 5 years, outpacing consumer prices overall, according to the Federal Reserve Bank of St. Louis.

This post appeared first on NBC NEWS